Program
Adalimumab
Also written as “adalimumab”, “MSB11022” and “M923”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.
Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbottits history only | 620 open or running | phase 4since Sep 13, 2005 | Nov 1, 2002 | none ahead |
| AbbVieits history only | 543 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | Sep 2027phase 2 · NCT06257875 |
| Alvotech Swissits history only | 60 open or running | phase 3since Feb 5, 2019 | Jun 8, 2018 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Fresenius Kabiits history only | 40 open or running | phase 3since Jan 17, 2016 | Jan 17, 2016 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Mar 31, 2016 | Mar 16, 2015 | none ahead |
| Cinnagenits history only | 20 open or running | phase 3since May 24, 2017 | May 24, 2017 | none ahead |
| Sino Biopharmaceuticalits history only | 22 open or running | phase 4since Apr 8, 2026 | Apr 8, 2026 | Apr 2028phase 4 · NCT07529925 |
| Takedaits history only | 20 open or running | phase 4since May 5, 2016 | Mar 15, 2015 | none ahead |
| Viatrisits history only | 20 open or running | phase 3since Nov 9, 2015 | Jun 3, 2015 | none ahead |
| care-arthritis-ltdits history only | 10 open or running | phase 2since Feb 24, 2015 | Feb 24, 2015 | none ahead |
| Celltrion | 10 open or running | phase 3since Sep 18, 2019 | Sep 18, 2019 | none ahead |
| LG Chemits history only | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| mabscale-llcits history only | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| National Resilienceits history only | 10 open or running | phase 3since Jan 10, 2021 | Jan 10, 2021 | none ahead |
| prestige-biopharma-limitedits history only | 11 open or running | phase 1since Oct 1, 2021 | Oct 1, 2021 | Jun 2027phase 1 · NCT05108259 |
| Samsung Bioepisits history only | 10 open or running | phase 1since Aug 13, 2020 | Aug 13, 2020 | none ahead |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Celltrion only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923
- Sep 18, 2019First study: phase 3 study in Arthritis, RheumatoidFirst studyNCT04171414 · 62 enrolled · Poland
TargetBeta
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| CHS-1420rule | nanjing-king-friend-biochemical-pharmaceutical-co-ltd | phase 3 | 2 |
| brivekimig | Sanofi | phase 2 | 6 |
| Hadlimarule | biora-therapeutics-inc | phase 1 | 1 |
Studies
The one study Celltrion leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04171414Arthritis, Rheumatoid · Poland | 3 | Completed | Nov 4, 2019 | 62 |
How it is read
Names in the registry
- “Adalimumab”, 69 entries
- “adalimumab”, 63 entries
- “MSB11022”, 3 entries
- “M923”, 3 entries
- “Humira (adalimumab)”, 3 entries
Codes read as this program: AVT02.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 45 studies
- Psoriasis, 25 studies
- Crohn Disease, 23 studies
- Colitis, Ulcerative, 9 studies
- Hidradenitis Suppurativa, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.